Increasing the specificity of chemotherapy may improve the efficacy of cancer treatment. Toward this aim, we developed a strain of bacteria to express enzymes for selective prodrug activation and non-invasive imaging in tumors. b-glucuronidase and the luxCDABE gene cluster were expressed in the DH5a strain of Escherichia coli to generate DH5a-lux/bG. These bacteria emitted light for imaging and hydrolyzed the glucuronide prodrug 9ACG to the topoisomerase I inhibitor 9-aminocamptothecin (9AC). By optical imaging, colony-forming units (CFUs) and staining for bG activity, we found that DH5a-lux/bG preferentially localized and replicated within CL1-5 human lung tumors in mice. The intensity of luminescence, CFU and bG activity increased with time, indicating bacterial replication occurred in tumors. In comparison with DH5a-lux/bG, 9AC or 9ACG treatment, combined systemic administration of DH5a-lux/bG followed by 9ACG prodrug treatment significantly (Po0.005) delayed the growth of CL1-5 tumors. Our results demonstrate that prodrug-activating bacteria may be useful for selective cancer chemotherapy.
Introduction
Methods that increase the therapeutic index of chemotherapy may potentially improve treatment efficacy and reduce side effects associated with systemic drug delivery. Selective activation of prodrugs at cancer cells is an attractive method to increase treatment specificity. 1 Tumor selective activation can be achieved by designing prodrugs that are activated by endogenous enzymes that are naturally enriched by cancer cells. 2 Differences between enzyme expression in tumor and normal tissues, however, may be minor. Prodrug-activating enzymes can also be targeted to cancer cells as immunoenzymes 3, 4 or by delivery of genes that encode for specific enzymes, 5 but effective delivery of these agents to tumors is inefficient. An improved approach to allow selective targeting and high expression of prodrug-activating enzymes at cancer cells is required to realize the potential of targeted prodrug therapy of cancer.
Recently, several genera of bacteria have been shown to specifically accumulate and replicate within tumors, including Clostridium, 6,7 Salmonella 8,9 Bifidobacterium 10 and E. coli. 11 These bacteria can cause cancer cell death by competing for nutrients and/or by secreting toxic bacterial products. Systemically administered bacteria selectively replicated at tumor region may be dependent on various tumor-related factors. For example, tumor may release the regulatory cytokines (IL-10, IL-4, TGFb), 12, 13 downregulation of Fas or upregulation of FasL expression to escape immune clearance 14, 15 reducing the expression of vascular cell adhesion molecule-1 on endothelial cell to prevent immune effector cells to enter tumor tissue 16 and hypoxia-induced adenosine accumulation suppresses the function of activated immune cells 17 to provide an immunosuppressive or hypoxic environment for bacteria to replicate within tumors. Based on these findings, we wished to test whether bacterial delivery of the prodrug-activating enzyme bG could be achieved to allow selective intratumoral activation of a glucuronide prodrug 9ACG for cancer therapy (Figure 1 ). Targeted bG immunoenzymes and genes have been shown to selectively activate glucuronide prodrugs, 4, 18, 19 allow accumulation of high drug concentrations at the tumor site, 3 produce bystander killing of antigen-negative tumor cells 4 and generate long-lasting protective immunity to subsequent tumor challenge. 20 In addition, glucuronide derivatives of many anti-neoplastic agents have been synthesized and can be selected for a particular tumor type. Polar glucuronide prodrugs do not easily enter cells due to their charged carboxyl group. However, for E. coli bacteria, glucuronide compounds are easily transported into bG-expressing E. coli by a glucuronide transport system for conversion. 21 Targeted bG-expressing E. coli may therefore be an attractive strategy for specific conversion of glucuronide prodrugs for cancer therapy.
In the present study, we generated E. coli DH5a-lux/bG that express bG and the luxCDABE gene cluster for prodrug activation and luminance emission, respectively. We showed that the DH5a-lux/bG can hydrolyze glucuronide substrates and emit luminescence. They also allowed specific conversion of the glucuronide prodrug 9ACG to the topoisomerase I poison 9-aminocamptothecin (9AC). Through optical imaging and colony-forming unit we showed that the bacteria localize and replicate in human tumor xenografts and produce substantial antitumor activity in combination with systemic 9ACG prodrug therapy.
Materials and methods

Bacteria, cells and animals
phoA supE44 thi-1 gyrA96 relA1 tonA, Gibco Laboratories, Grand Island, NY, USA) were used in this study. CL1-5 cells, a highly invasive subline selected from CL1-0 human lung adenocarcinoma cells, were kindly provided by Dr PC Yang, Department of Internal Medicine, National Taiwan University Hospital (Taipei, Taiwan), 22 and were grown in Dulbecco's Minimal Essential Medium (Sigma, St Louis, MO, USA) supplemented with 5% heatinactivated bovine serum, 100 units ml À1 penicillin and 100 mg ml À1 streptomycin (Gibco Laboratories, Grand Island, NY, USA) at 37 1C in a 5% CO 2 humidified atmosphere. Six to eight-week-old nude mice were purchased from the National Laboratory Animal Center, Taipei, Taiwan. Animal experiments were performed in accordance with institute guidelines.
Plasmid construction pGHL6 23 was used as template for polymerase chain reaction amplification of the fen promoter with primers 5 0 -ATCGGCCACCCGGGTATGAAATTAAATAAT-3 0 and 5 0 -GCTCTAGAGTCGACCCCTCCAATTCTAA TT-3 0 to introduce EaeI and XbaI restriction sites. The fen promoter is derived from the fengycin synthetase operon and drives the expression of the antifungal antibiotics, fengcin, from Bacillus subtilis F29-3. The PCR fragment was digested with EaeI and XbalI, and cloned into pRSETB (Invitrogen, The Netherlands) in place of the T7 promoter to form pRSETB-fen. The gene coding E. coli bG (pRSETB-bG) was digested with PstI and HindIII and subcloned into pRSETB-fen to create pRSETB-fen-bG. The XLEPT7.3 plasmid 24 containing the luxCDABE gene cluster was a generous gift from Dr EA Meighen (Department of Biochemistry, McGill University, Montreal, Quebec, Canada). The luxCDABE gene cluster was excised with EcoRI and subcloned into pRSETB-fen to create pRSETB-fen-lux. Finally, the pRSETB-fen-bG plasmid was used as temple for PCR amplification of fen-bG with 5 0 -ATCCACGTAGTGCCC GCGCGTTGGCC-3 0 and 5 0 -CTGCAGCACTACGTGC TAGTTATTGCTCAG-3 0 primers. The PCR fragment was digested with DraIII and subcloned into pRSETBfen-lux to form pRSETB-lux/bG. The pRSETB-lux/bG plasmid was used to transform E. coli DH5a to produce light-emitting DH5a-lux/bG strains.
Analysis of luciferase and bG activity E. coli DH5a was transformed with pRSETB-fen, pRSETB-bG, pRSETB-lux or pRSETB-lux/bG. The 50 ml of transformed DH5a (OD 600 ¼ 0.5) were transferred into a 96-well white Plate (Nalge Nunc International, Naperville, IL) and the continuous bioluminescence emission were measured on a Top Count Luminescence Counter (Perkin-Elmer Life Sciences, Boston, USA), and the units were counts per second (CPS) per well. The bG activity of transformed DH5a strains was measured by monitoring the release of p-nitrophenol (PNP) from p-nitrophenyl-b-D-glucopyranoside (PNPG) conversion. Transformed DH5a strains were washed twice with PBS and 50 ml of transformed DH5a (OD 600 ¼ 0.5) was immediately mixed with 50 ml 3.2 mM PNPG in PBS containing 0.05% BSA, pH 7.4 at Toxicity of 9AC and pHAM to DH5a-lux/bG strains DH5a-lux/bG strains were cultured up to OD 600 ¼ 0.35, then the DH5a-lux/bG were subdivided into triplicate and incubated with graded amounts of 9AC, a topoisomerase I inhibitor, or p-hydroxyaniline mustard (pHAM), 25 an alkylating agent, at 37 1C for 3 and 6 h. The growth inhibition of DH5a-lux/bG was measured by the spectrophotometer at OD 600 nm .
Activation of 9-ACG by DH5a-lux/bG in vitro CL1-5 cells (5 Â 10 3 cells per well) grown overnight in 96-well microtiter plates were treated with graded concentrations of 9AC, 9ACG, bG (2 mg well À1 ) þ 9ACG or DH5a-lux/bG (2 Â 10 7 bacteria per well) þ 9ACG in medium that contained 25 mg ml À1 gentamycin and then incubated at 37 1C for 24 h. The cells were washed three times with PBS and then incubated an additional 24 h in fresh medium that contained 25 mg ml À1 gentamycin to kill residual bacteria. Cell viability was determined by the ATPlite luminescence ATP detection assay system (Perkin-Elmer Life and Analytical Science, Boston, MA). Results are expressed as percent inhibition of luminescence as compared to untreated cells by the following formula:
Àbackground luminescence=control luminescence Àbackground luminescenceÞ
In vivo bioluminescence imaging Group of three BALB/c nu/nu mice bearing established CL1-5 tumor (200-300 mm 3 ) in their right flank was intravenously (i.v.) (tail vein) injected with 4 Â 10 7 lightemitting DH5a-lux/bG bacteria. Mice were anesthetized with isofluran using the XGI-8 gas anesthesia system (Xenogen, Alameda, USA) and whole-body images were acquired at the indicated times (24, 48 , and 72 h) by a cooled Charge Coupled Device camera (Xenogen IVIS 50, Xenogen, Alameda, USA). After 72 h, different tissues, CL1-5 tumor, liver, kidney, stomach, colon, intestine, were removed and imaged by Charge Coupled Device camera.
Histological analysis of DH5a-lux/bG bacteria in tumors CL1-5 tumors (200-300 mm 3 ) were excised at 0, 24, 48, 72 h after i.v. tail vein injection of 4 Â 10 7 DH5a-lux/bG bacteria, embedded in Tissue-Tek OCT compound (Sakura, USA) in liquid nitrogen, and cut into 20 mm sections. Tumor sections were stained for bG activity with the GUS b-Glucuronidase Reporter Gene Staining kit (Sigma). Briefly, the sections were placed in fixation solution (10 mM MES, pH 5.6, with 300 mM mannitol and 0.3% formaldehyde) at room temperature for 45 min, washed three times with wash solution (10 mM sodium phosphate, pH 7.0, with 0.2 mM EDTA), and stained with 5-bromo-4-chloro-3-indolyl b-D-glucuronide (X-GlcA) at 37 1C for 3 h. The sections were then stained with nuclear fast red (Sigma) as a counter stain. All sections were examined on an upright microscope (Olympus BX41, Japan).
Analysis of DH5a-lux/bG in tumor and normal tissues DH5a-lux/bG was administered by i.v. tail vein injection into BALB/c nu/nu mice (n ¼ 3) bearing established CL1-5 tumor (200-300 mm 3 ). At 24, 48, 72 h after injection, the tumors and organs were removed, weighed and homogenized in sterile LB medium. The homogenate was then plated onto LB plate that contains 100 mg ml À1 ampicilin and incubated for 24 h at 37 1C. The colonyforming units per mg of tissues were determined by counting colonies and dividing them by the weight of the tumors and specific organs.
In vivo antitumor activity Groups of 4-5 Balb/c nude mice bearing 100-300 mm 
Statistical analysis
Statistical significance of differences between mean values was estimated with Excel (Microsoft, Redmond, WA, USA) using the independent t-test for unequal variances. P-values of o0.05 were considered statistically significant.
Results
Characterization of luminescence and bG-expressing E. coli (DH5a). The plasmid pRSETB-lux/bG, which contains the lux-CDABE-based bioluminescent reporter and E. coli bG genes are under the control of two fen promoters (Figure 2a) , was transformed into DH5a bacteria to generate the DH5a-lux/bG strain. The activities of the luxCDABE and bG genes in DH5a-lux/bG were analyzed by bioluminescent and bG microassays. DH5a-lux/bG bacteria displayed stable luminescence emission without addition of exogenous substrate; the bioluminescence intensity in both DH5a-lux/bG and DH5a-lux bacteria was about 100-fold higher than in control DH5a-vector or DH5a-bG bacteria (Figure 2b ). DH5a-Lux/bG and DH5a-bG bacteria hydrolyzed the b-glucuronidase substrate PNPG, and converted it to PNP, showing that these strains expressed functional bG (Figure 2c ).
The toxicity of 9AC and pHAM to bacteria Active drug released by hydrolysis of glucuronide anticancer prodrug may also influence the viability of DH5a-lux/bG bacteria. Therefore, we investigated the toxicity of two glucuronide prodrug products, the mammalian topoisomerase I inhibitor 9AC and the alkylating agent pHAM, on DH5a-lux/bG viability. We incubated DH5a-lux/bG with graded concentrations of 9AC or pHAM for 3 and 6 h and measured bacterial density at an absorbance of 600 nm. pHAM, but not 9AC, inhibited the growth of DH5a-lux/bG in a time-dependent manner (Figure 3 ), indicating that 9AC does not inhibit prokaryotic topoisomerase. This suggests that 9ACG is a good prodrug candidate for DH5a-lux/bG targeted activation.
Activation of 9ACG by DH5a-lux/bG in vitro
To examine if DH5a-lux/bG hydrolysis of 9ACG could inhibit the growth of human cancer cells in vitro, CL1-5 human lung cancer cells were incubated with 9AC, 9ACG, 9ACG mixed with E. coli bG, or 9ACG mixed with DH5a-lux/bG bacteria. The cellular ATP synthesis rate after drug treatment was measured as an index of cell viability. The IC 50 value of cells treated with 9ACG plus DH5a-lux/bG bacteria (138 nM) was near to the IC 50 value observed when cells were treated with 9AC (52 nM) Figure 3 Toxicity of 9AC and pHAM to DH5a-lux/bG. DH5a-lux/bG was incubated with graded concentrations of 9AC (K, m) or pHAM (J, n) at 37 1C for 3 h (K, J) and 6 h (m, n) and the survival of DH5a-lux/bG was measured at 600 nm. Results show the mean survival of treated DH5a-lux/bG relative to untreated DH5a-lux/bG. Bars, s.e. of triplicate determinations. In vivo tumor localization and distribution of DH5a-Lux/bG To determine whether DH5a-lux/bG bacteria could specifically target to tumors in vivo, Balb/c nu/nu mice bearing established CL1-5 tumors (B200 mm 3 ) in the right flank were i.v. injected with DH5a-lux/bG. The mice were then imaged after 24, 48, and 72 h. Figure 5a shows that DH5a-lux/bG was selectively retained in CL1-5 tumors and the intensity of luminescence increasing with time, indicating that DH5a-lux/bG could replicate within tumors. In addition, to verify the luminescence results, tumor sections were stained with X-GlcA to examine for the presence of functional bG activity. Figure 5b shows that tumor sections displayed a time-dependent increase in blue X-GlcA staining, indicating bG activity also increased in tumors with time. These results demonstrate that functional DH5a-lux/bG could be selectively retained in tumors to allow prodrug activation. Although DH5a-lux/bG preferentially accumulates in CL1-5 tumors, it may also localize on normal tissues. Therefore, the luminescence of isolated tissues of tumor-bearing mice at 72 h after DH5a-lux/bG injection was imaged with the IVIS s Imaging System 50. Figure 5c shows that CL1-5 tumor display obvious luminescence as compared with other tissues (liver, kidney, stomach, colon, intestine, CL1-5 tumor) and only little luminescence remained in colon. In addition, the tissues distribution pattern of DH5a-lux/bG bearing mice was also measured at different times by counting the colony-forming unit per mg tissues. Figure 5d also shows that DH5a-lux/bG accumulates preferentially in tumors and the tumor-tonormal tissues ratios were about 12-62:1, 47-450:1 and 33-1054:1 at 24, 48 and 72 h, respectively. Lastly, CL1-5 tumors but not colons or other organs, remained luminescent up to 120 h after DH5a-lux/bG inoculation with or without prodrug therapy (data not shown). In conclusion, these results suggested that DH5a-lux/bG could selectively replicate in CL1-5 tumor in vivo.
Targeted activation of 9ACG prodrug in vivo
The antitumor activity of DH5a-lux/bG in combination with 9ACG prodrug was examined in Balb/c nu/nu mice bearing established 100-300 mm 3 CL1-5 tumors. The combined prodrug therapy consisted of an i.v. tail vein injection of 4 Â 10 7 c.f.u. DH5a-lux/bG on day 12 and fractionated i.v. tail vein injection administration of 50 mg kg À1 9ACG on days 14 and 15. Control groups of tumor-bearing mice were also treated with PBS, DH5a-lux/bG alone, 9ACG alone or subcutaneously injected with 9AC. Combined treatment with 9ACG and DH5a-lux/bG significantly (Po0.005) delayed tumor growth as compared to each individual treatment with DH5a-lux/ bG alone, 9ACG alone, 9AC or PBS (Figure 6a ). The toxicity of combined treatment was minimal with a maximum weight loss of 7% and no significant (P40.05) weight loss was observed compared to each individual treatment with DH5a-lux/bG alone, 9ACG alone (Figure 6b ). In contrast, 9AC treatment caused a maximum weight loss of 15%. These results demonstrate that bacteria-targeted activation of glucuronide prodrugs may be useful for selective cancer chemotherapy.
Discussion
We developed a tumor-targeted luminescence-emitting and bG-expressing bacteria (DH5a-lux/bG) as a prodrugactivating factory to convert glucuronide prodrugs to antineoplastic agents for selective chemotherapy. In the presence of DH5a-lux/bG, the glucuronide prodrug 9ACG was effectively hydrolyzed to release 9AC with similar toxicity as the parent drug 9AC. The intensity of luminescence and bG activity in CL1-5 tumors increased with time, indicating the light-emitting bG-expressing DH5a-lux/bG preferentially replicated in CL1-5 tumor in vivo. In comparison with control bacteria and prodrug treatment, combination treatment of DH5a-lux/bG and 9ACG significantly delayed the growth of tumors, showing that tumor targeted prodrug-activating bacteria may be useful for selective cancer chemotherapy.
Bacteria that selectively replicate in tumors have shown promising preliminary results. Several genetically-engineered attenuated microorganisms, including Listeria, Clostridium, Salmonella, Bifidobacterium, and E. coli, have demonstrated potential as tumor targeting vectors both for their tumoricidal activity and for their ability to deliver therapeutic genes to inaccessible regions of tumors. [6] [7] [8] [9] [10] For example, Yu et al. 11 demonstrated the real-time visualization of the location, survival and replication of light-emitting bacteria in implanted tumors and their metastases in live animals. Our results also show that DH5a-lux/bG preferentially localized and replicated in CL1-5 tumor in vivo. The mechanisms that result bacteria to accumulate at tumor regions are likely to be various tumor-related factors. Solid tumor contains hypoxic region, 26, 27 which is well adapted by facultative anaerobes such as E. coli but decreases the bactericidal activity of macrophages and neutrophils. In addition, the tumor may provide an immunosuppressive environment that contributes to the ability of E. coli to multiply within tumors. For example, Griffioen et al. indicated that tumors downregulate vascular cell adhesion molecule-1 expression on endothelial cells, which modulate immune cells-vessel wall interaction and decrease the effector's cells to enter tumor tissue. 16 Sitkovsky et al. 17 showed that hypoxia-induced adenosine and adenosine receptortriggered signaling can block innate and adaptive immune responses to prevent tissues damage from inflammatory damage and also protect cancerous tissues by inhibiting incoming antitumor T lymphocytes, 28 Le et al. showed that a novel hypoxia-induced galectin-1 protein modulates tumor immune privilege in vivo. 29 These results suggest that tumor microenvironment may provide a sanctuary for a small number of bacteria that will escape the immune clearance. Therefore, bacteria may be a good candidate for tumor-targeting vector to carry therapeutic genes for the cancer treatment.
bG is an attractive enzyme for specific conversion of glucuronide prodrugs for cancer therapy. A wide variety of glucuronide prodrugs are available, including prodrugs of effective antineoplastic agents such as doxorubicin, 30 etoposide, 31 paclitaxel, 32 docetaxel 33 and alkylating agents. 34 Glucuronide derivatives of most antineoplastic agent can be synthesized by employing linkers between the drug and glucuronide moieties. 34, 35 This is a major advantage since the appropriate prodrugs can be selected for a particular tumor type. bG is located in lysosomes 36 and only very low level of bG is found in human serum. 37 Glucuronides are charged at physiological pH values which hinders their diffusion across the plasma membrane of mammalian cells, 38 effectively sequestering glucuronides from contact with endogenous bG. However, in this study, the glucuronide derivative 9ACG or PNPG was shown to be hydrolyzed easily by bG-expressing DH5a bacteria to release 9AC, an anti-tumor alkaloid that inhibits topoisomerase I, or PNP. The reason may be that bG-expressing E. coli DH5a has a glucuronide transport system (gusBC genes) responsible for the uptake of glucuronide compounds and then activation. 21 Moreover, we found that 9AC was nontoxic to DH5a, verifying that 9AC is specific for mammalian topoisomerase I. 9ACG thus appears to be a suitable prodrug for cancer treatment by bG-expressing DH5a bacteria.
The utilization of bacteria in gene therapy is a recent strategy that has proven in vivo anti-tumor efficacy. 39, 40 However, the low tumor colonization efficiency of the strains employed to date requires high bacterial doses and can lead to septic shock. 41 Expression of tumor-specific single chain antibodies on the bacterial surface may increase the efficacy of bacterial tumor targeting in vivo. 42 In addition, we previously showed that hydrolysis of glucuronide prodrugs by anchoring bG on the cell membrane produces potent cytotoxicity and bystander killing of neighboring enzyme-negative cells, 4 which could overcome the low gene transduction efficiencies in vivo. Therefore, surface expression of bG on bacteria may increase enzyme activity and maximize the therapeutic efficacy of bG-expressing bacteria for glucuronide prodrugs.
In summary, we demonstrated that the light emitting and bG-expressing DH5a-lux/bG could specifically convert 9ACG to 9AC in vitro and replicate and accumulate in tumors in vivo. Combination treatment with DH5a-lux/ bG and 9ACG significantly delayed tumor growth with minimal toxicity in comparison to therapy with bacteria or prodrug chemotherapy alone. These data provided a new rationale for expressing of prodrug-activating enzymes from conditionally replicating bacteria to allow development of tumor-specific gene therapy protocols.
